STAAR Surgical (STSX) is a medical device company that designs and manufactures surgical instruments for use in ophthalmic procedures. The company's products are used to treat cataracts, glaucoma, and other eye conditions.
On July 14, 2021, STAAR Surgical reported its second quarter financial results for the period ended June 30, 2021. The company's revenue for the quarter was $57.9 million, which represents a 6.8% increase compared to the same period in the previous year. Net income for the quarter was $4.5 million, which represents a 10.6% increase compared to the same period in the previous year.
In addition to its financial performance, STAAR Surgical also announced that its stock had begun trading on The NASDAQ Global Select Market under the symbol "STAA." This marks a significant milestone for the company as it continues to grow and expand its business.
The 7.9% increase in trading volume of STAA is likely due to increased investor interest in the company's stock following its successful IPO on The NASDAQ Global Select Market. This increase in demand for the stock may also be driven by the company's strong financial performance and growth prospects.
Overall, the news of STAAR Surgical's successful IPO and increased trading volume is a positive development for the company and its shareholders. The company's focus on innovation and excellence in ophthalmic surgery is likely to continue driving growth and success in the years to come.
Published 298 days ago